Chronic infection by mucoid pseudomonas aeruginosa associated with dysregulation in T-cell immunity to outer membrane porin F

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 11, 2015, Pages 1250-1264

  Quigley, Kathryn J ^a   Reynolds, Catherine J ^a   Goudet, Amelie ^b   Raynsford, Eleanor J ^a   Sergeant, Ruhena ^a   Quigley, Andrew ^c   Worgall, Stefan ^d   Bilton, Diana ^e   Wilson, Robert ^e   Loebinger, Michael R ^e   Maillere, Bernard ^b   Altmann, Daniel M ^a   Boyton, Rosemary J ^a,e  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CEA SACLAY   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adaptive immunity; Bronchiectasis; Epitopes; Pseudomonas; T lymphocyte

Indexed keywords

CHEMOKINE; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; OUTER MEMBRANE PORIN F; PORIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BRONCHIECTASIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPUTUM; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; LONGITUDINAL STUDY; LUNG; T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; ANIMALS; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MICE; MIDDLE AGED; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84930461892     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201411-1995OC     Document Type: Article

References (62)

1. Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 2010;15:1037-1056.
2. Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007;2: 153-164.
3. Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525-532.
4. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34: 843-849.
5. May TB, Shinabarger D, Maharaj R, Kato J, Chu L, DeVault JD, Roychoudhury S, Zielinski NA, Berry A, Rothmel RK, et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991;4:191-206.
6. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002;3: 593-603.
7. Song Z, Wu H, Ciofu O, Kong KF, Høiby N, Rygaard J, Kharazmi A, Mathee K. Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. J Med Microbiol 2003;52: 731-740.
8. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J Immunol 2005;175:7512-7518.
9. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2012;186:420-427.
10. Döring G, Meisner C, Stern M; Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007;104: 11020-11025.
11. Krause A, Whu WZ, Qiu J, Wafadari D, Hackett NR, Sharma A, Crystal RG, Worgall S. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol 2013; 173:230-241.
12. Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother 2014;10:170-183.
13. Thomas LD, Cripps AW, Kyd JM. Immune response mechanisms against Pseudomonas aeruginosa associated with mucosal immunization with protein antigens in a rat model of acute lung infection. Vaccine 2009;27:3324-3330.
14. Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008;26:1011-1024.
15. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004;22:840-847.
16. Weimer ET, Ervin SE, Wozniak DJ, Mizel SB. Immunization of young African green monkeys with OprF epitope 8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 2009;27:6762-6769.
17. Mutharia LM, Hancock RE. Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun 1983;42:1027-1033.
18. Mutharia LM, Nicas TI, Hancock RE. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J Infect Dis 1982;146: 770-779.
19. Yoshimura F, Zalman LS, Nikaido H. Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem 1983;258:2308-2314.
20. Gilleland HE Jr, Gilleland LB, Matthews-Greer JM. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun 1988;56:1017-1022.
21. Gilleland HE Jr, Parker MG, Matthews JM, Berg RD. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun 1984;44:49-54.
22. Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF. Vaccine 2011;29:2131-2139.
23. Matthews-Greer JM, Gilleland HE Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J Infect Dis 1987;155:1282-1291.
24. Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, Gilleland HE Jr. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 2001;69: 3510-3515.
25. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 2005;115:1281-1289.
26. Boyton RJ. Regulation of immunity in bronchiectasis. Med Mycol 2009; 47:S175-S182.
27. Boyton RJ, Reynolds CJ, Quigley KJ, Altmann DM. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin Exp Immunol 2013;171:117-123.
28. Boyton RJ, Smith J, Ward R, Jones M, Ozerovitch L, Wilson R, Rose M, Trowsdale J, Altmann DM. HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006;173:327-333.
29. Boyton RJ, Smith J, Jones M, Reynolds C, Ozerovitch L, Chaudhry A, Wilson R, Rose M, Altmann DM. Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin Exp Immunol 2008;152:95-101.
30. Boyton RJ, Reynolds C, Wahid FN, Jones MG, Ozerovitch L, Ahmad T, Chaudhry A, Jewell DP, Kon OM, Smith J, et al. IFN gamma and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. Tissue Antigens 2006;68:325-330.
31. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
32. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to pseudomonas aeruginosa induced with a capsidmodified adenovirus expressing P. aeruginosa OprF. J Virol 2007;81: 13801-13808.
33. Chu KK, Tippayawat P, Walker NJ, Harding SV, Atkins HS, Maillere B, Bancroft GJ, Lertmemongkolchai G, Altmann DM. CD41 T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis. Eur J Immunol 2011;41:107-115.
34. Till SJ, Raynsford EJ, Reynolds CJ, Quigley KJ, Grzybowska-Kowalczyk A, Saggar LR, Goldstone A, Maillere B, Kwok WW, Altmann DM, et al. Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax 2014;69: 335-345.
35. Ascough S, Ingram RJ, Chu KK, Reynolds CJ, Musson JA, Doganay M, Metan G, Ozkul Y, Baillie L, Sriskandan S, et al. Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD41 T cell immunity. PLoS Pathog 2014;10:e1004085.
36. Reynolds CJ, Jones C, Blohmke CJ, Darton TC, Goudet A, Sergeant R, Maillere B, Pollard AJ, Altmann DM, Boyton RJ. The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles. Immunology 2014;143:438-446.
37. Caballero E, Drobnic ME, Pérez MT, Manresa JM, Ferrer A, Orriols R. Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis. Thorax 2001;56:669-674.
38. Rawling EG, Brinkman FS, Hancock RE. Roles of the carboxy-terminal half of Pseudomonas aeruginosa major outer membrane protein OprF in cell shape, growth in low-osmolarity medium, and peptidoglycan association. J Bacteriol 1998;180:3556-3562.
39. Azghani AO, Idell S, Bains M, Hancock RE. Pseudomonas aeruginosa outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. Microb Pathog 2002;33:109-114.
40. Wu L, Estrada O, Zaborina O, Bains M, Shen L, Kohler JE, Patel N, Musch MW, Chang EB, Fu YX, et al. Recognition of host immune activation by Pseudomonas aeruginosa. Science 2005;309: 774-777.
41. Fito-Boncompte L, Chapalain A, Bouffartigues E, Chaker H, Lesouhaitier O, Gicquel G, Bazire A, Madi A, Connil N, Véron W, et al. Full virulence of Pseudomonas aeruginosa requires OprF. Infect Immun 2011;79:1176-1186.
42. van Gennip M, Christensen LD, Alhede M, Qvortrup K, Jensen PØ, Høiby N, Givskov M, Bjarnsholt T. Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo. Infect Immun 2012;80: 2601-2607.
43. Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A, De Rosa G, Mascolo M, Ortega De Luna L, Catania MR, et al. Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiol 2010;10:9.
44. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16:319-323.
45. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, Goulder PJ, Walker BD, Brander C, Mullins JI. Broad and Gagbiased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 2008;3:e1424.
46. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, Piaskowski SM, Duan L, Seese A, Gladden AD, et al. Vaccineinduced CD81 T cells control AIDS virus replication. Nature 2012; 491:129-133.
47. Garris CS, Blaho VA, Hla T, Han MH. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology 2014;142:347-353.
48. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, Dehlink E, Nachbaur E, Horak F, Jaksch P, et al. A Th17-and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013;187:621-629.
49. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
50. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, Ackerman K, Haley K, Galle PR, Szabo SJ, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002;295:336-338.
51. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21: 713-758.
52. McLane LM, Banerjee PP, Cosma GL, Makedonas G, Wherry EJ, Orange JS, Betts MR. Differential localization of T-bet and Eomes in CD8 T cell memory populations. J Immunol 2013;190:3207-3215.
53. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012;36:55-67.
54. Powell N, Walker AW, Stolarczyk E, Canavan JB, Gökmen MR, Marks E, Jackson I, Hashim A, Curtis MA, Jenner RG, et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor1 innate lymphoid cells. Immunity 2012;37: 674-684.
55. Heckman KL, Radhakrishnan S, Peikert T, Iijima K, McGregor HC, Bell MP, Kita H, Pease LR. T-bet expression by dendritic cells is required for the repolarization of allergic airway inflammation. Eur J Immunol 2008;38:2464-2474.
56. Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P. T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci USA 2013;110:E3216-E3224.
57. Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, Chi H. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol 2009;10:769-777.
58. Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf 2014;13:989-998.
59. Chan YR, Chen K, Duncan SR, Lathrop KL, Latoche JD, Logar AJ, Pociask DA, Wahlberg BJ, Ray P, Ray A, et al. Patients with cystic fibrosis have inducible IL-171IL-221 memory cells in lung draining lymph nodes. J Allergy Clin Immunol 2013;131:1117-1129, e1-e5.
60. Hector A, Schäfer H, Pöschel S, Fischer A, Fritzsching B, Ralhan A, Carevic M, Öz H, Zundel S, Hogardt M, et al. Regulatory T cell impairment in cystic fibrosis patients with chronic Pseudomonas infection. Am J Respir Crit Care Med [online ahead of print] 29 Jan 2015; DOI: 10.1164/rccm.201407-1381OC.
61. Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014;35:51-60.
62. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/ MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004;1:e33.